{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:07:32Z","timestamp":1780103252687,"version":"3.54.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009473","name":"Universidad de M\u00e1laga","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009473","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.bmc.2026.118645","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:58:32Z","timestamp":1774972712000},"page":"118645","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Wee1-targeting inhibitors: From virtual screening to lead discovery"],"prefix":"10.1016","volume":"138","author":[{"given":"Jochem","family":"Nelen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bidisha","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Jim\u00e9nez-Bernad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia C.","family":"Darragh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole B.","family":"Servant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirza","family":"Jahic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Villalgordo-Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunda I.","family":"Georg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horacio","family":"P\u00e9rez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2026.118645_bb0005","article-title":"A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target, j. hematol. oncol","volume":"13","author":"di Ror\u00e0","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.bmc.2026.118645_bb0010","doi-asserted-by":"crossref","first-page":"7863","DOI":"10.1021\/acs.jmedchem.7b00996","article-title":"Structural basis of wee kinases functionality and inactivation by diverse small molecule inhibitors","volume":"60","author":"Zhu","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118645_bb0015","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.tips.2016.06.006","article-title":"Targeting WEE1 kinase in cancer","volume":"37","author":"Matheson","year":"2016","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.bmc.2026.118645_bb0020","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41392-020-0150-x","article-title":"DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer","volume":"5","author":"Huang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.bmc.2026.118645_bb0025","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrc.2016.138","article-title":"Cell cycle proteins as promising targets in cancer therapy","volume":"17","author":"Otto","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmc.2026.118645_bb0030","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910689","article-title":"Wee1 kinase: a potential target to overcome tumor resistance to therapy","volume":"22","author":"Esposito","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2026.118645_bb0035","first-page":"8211","article-title":"Radiosensitization of p53 mutant cells by PD0166285, a novel g(2) checkpoint abrogator","volume":"61","author":"Wang","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2026.118645_bb0040","doi-asserted-by":"crossref","first-page":"4896","DOI":"10.1021\/jm0512591","article-title":"4-Phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione inhibitors of the checkpoint kinase wee1. Structure\u2212activity relationships for chromophore modification and phenyl ring substitution","volume":"49","author":"Palmer","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118645_bb0045","doi-asserted-by":"crossref","first-page":"514","DOI":"10.4161\/cbt.9.7.11115","article-title":"MK-1775, a small molecule wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil","volume":"9","author":"Hirai","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.bmc.2026.118645_bb0050","doi-asserted-by":"crossref","first-page":"5638","DOI":"10.1158\/1078-0432.CCR-11-0650","article-title":"MK-1775, a novel wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells","volume":"17","author":"Bridges","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2026.118645_bb0055","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1158\/1535-7163.MCT-13-0025","article-title":"Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy","volume":"12","author":"Guertin","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmc.2026.118645_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104710","article-title":"WEE1 inhibition in cancer therapy: mechanisms, synergies, preclinical insights, and clinical trials","volume":"211","author":"Thangaretnam","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.bmc.2026.118645_bb0065","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1200\/jco.2009.27.15_suppl.3510","article-title":"A phase i and pharmacological study of MK-1775, a wee1 tyrosine kinase inhibitor, in both monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors","volume":"27","author":"Schellens","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bmc.2026.118645_bb0070","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11912-021-01098-8","article-title":"WEE1 inhibitor: clinical development","volume":"23","author":"Kong","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.bmc.2026.118645_bb0075","doi-asserted-by":"crossref","first-page":"13004","DOI":"10.1021\/acs.jmedchem.1c01121","article-title":"Discovery of ZN-c3, a highly potent and selective wee1 inhibitor undergoing evaluation in clinical trials for the treatment of cancer","volume":"64","author":"Huang","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118645_bb0080","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2021-CT016","article-title":"Abstract CT016: clinical activity of single-agent ZN-c3, an oral WEE1 inhibitor, in a phase 1 dose-escalation trial in patients with advanced solid tumors","volume":"81","author":"Tolcher","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2026.118645_bb0085","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7077","article-title":"A phase 1\/2 dose escalation study of the BCL-2 inhibitor ZN-d5 and the WEE1 inhibitor azenosertib (ZN-c3) in patients (pts) with acute myeloid leukemia (AML)","volume":"41","author":"Smith","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bmc.2026.118645_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117312","article-title":"Discovery of pyrido[4,3-d]pyrimidinone derivatives as novel wee1 inhibitors","volume":"87","author":"Ye","year":"2023","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2026.118645_bb0095","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.chembiol.2019.10.013","article-title":"Development and characterization of a wee1 kinase degrader","volume":"27","author":"Li","year":"2020","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.bmc.2026.118645_bb0100","first-page":"1","article-title":"PROTACs: great opportunities for academia and industry","volume":"4","author":"Sun","year":"2019","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.bmc.2026.118645_bb0105","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1158\/1538-7445.AM2019-4423","article-title":"Abstract 4423: antitumor activity of the novel oral highly selective wee1 inhibitor debio 0123","volume":"79","author":"O'Dowd","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2026.118645_bb0110","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.2024.42.16_suppl.3120","article-title":"Results of a phase 1, dose-finding study of debio 0123 as monotherapy in adult patients with advanced solid tumors: safety, pharmacokinetic, and preliminary antitumor activity data","volume":"42","author":"Papadopoulos","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bmc.2026.118645_bb0115","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1200\/JCO.2023.41.16_suppl.3012","article-title":"Debio 0123-101: a phase 1 trial of debio 0123 in combination with carboplatin in advanced solid tumors\u2014safety, pharmacokinetic, and preliminary antitumor activity data","volume":"41","author":"Gelderblom","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bmc.2026.118645_bb0120","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1021\/acs.jcim.3c01982","article-title":"ESSENCE-dock: a consensus-based approach to enhance virtual screening enrichment in drug discovery","volume":"64","author":"Nelen","year":"2024","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.bmc.2026.118645_bb0125","doi-asserted-by":"crossref","unstructured":"C. O'Dowd, G. Gavory, F. Burkamp, A. Treder, C. Boyd, T. Harrison, F. Massi\u00e8re, A. Gl\u00fcck, A. Thorimbert, C. Chardonnens, A. Zaffalon, S. Rigotti, R. Mader, G. Vuagniaux, A. Vaslin, Antitumor Activity of the Novel Oral Highly Selective Wee1 inhibitor Debio 0123, (n.d.). https:\/\/www.debiopharm.com\/wp-content\/uploads\/2019\/04\/2019-Debio-0123-poster-AACR.pdf.","DOI":"10.1158\/1538-7445.AM2019-4423"},{"key":"10.1016\/j.bmc.2026.118645_bb0130","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nchem.1243","article-title":"Quantifying the chemical beauty of drugs","volume":"4","author":"Bickerton","year":"2012","journal-title":"Nat Chem"},{"key":"10.1016\/j.bmc.2026.118645_bb0135","series-title":"The PyMOL molecular graphics system, Version 2.6.2","author":"Schr\u00f6dinger, LLC","year":"2025"},{"key":"10.1016\/j.bmc.2026.118645_bb0140","doi-asserted-by":"crossref","first-page":"W463","DOI":"10.1093\/nar\/gkaf361","article-title":"PLIP 2025: introducing protein\u2013protein interactions to the protein\u2013ligand interaction profiler","volume":"53","author":"Schake","year":"2025","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.bmc.2026.118645_bb0145","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1021\/acschembio.7b00147","article-title":"Dual targeting of WEE1 and PLK1 by AZD1775 elicits single agent cellular anticancer activity","volume":"12","author":"Wright","year":"2017","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.bmc.2026.118645_bb0150","doi-asserted-by":"crossref","unstructured":"S. Baldi, N. Long, S. Ma, L. Liu, A. Al-Danakh, Q. Yang, X. Deng, J. Xie, H. Tang, Advancements in protein kinase inhibitors: from discovery to clinical applications, Research (Wash, DC) 8 (n.d.) 0747. doi:10.34133\/research.0747.","DOI":"10.34133\/research.0747"},{"key":"10.1016\/j.bmc.2026.118645_bb0155","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1021\/ci800166p","article-title":"Lead finder: an approach to improve accuracy of protein\u2212ligand docking, binding energy estimation, and virtual screening","volume":"48","author":"Stroganov","year":"2008","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.bmc.2026.118645_bb0160","doi-asserted-by":"crossref","DOI":"10.1186\/s13321-021-00522-2","article-title":"GNINA 1.0: molecular docking with deep learning","volume":"13","author":"McNutt","year":"2021","journal-title":"J Cheminform"},{"key":"10.1016\/j.bmc.2026.118645_bb0165","series-title":"DiffDock: diffusion steps, twists, and turns for molecular docking","author":"Corso","year":"2023"},{"key":"10.1016\/j.bmc.2026.118645_bb0170","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1021\/acs.jcim.5b00654","article-title":"Better informed distance geometry: using what we know to improve conformation generation","volume":"55","author":"Riniker","year":"2015","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.bmc.2026.118645_bb0175","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J Comput Chem"},{"key":"10.1016\/j.bmc.2026.118645_bb0180","unstructured":"Schr\u00f6dinger Release 2024-3: Maestro, Schr\u00f6dinger, LLC, New York, NY, 2024. (n.d.)."},{"key":"10.1016\/j.bmc.2026.118645_bb0185","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1021\/acs.jctc.1c00302","article-title":"OPLS4: improving force field accuracy on challenging regimes of chemical space","volume":"17","author":"Lu","year":"2021","journal-title":"J Chem Theory Comput"},{"key":"10.1016\/j.bmc.2026.118645_bb0190","unstructured":"bio-hpc, bio-hpc\/metascreener, (2025). https:\/\/github.com\/bio-hpc\/metascreener (accessed January 23, 2025)."},{"key":"10.1016\/j.bmc.2026.118645_bb0195","unstructured":"Nelen J. Jnelen\/DiffDockHPC, (2025). https:\/\/github.com\/Jnelen\/DiffDockHPC (accessed January 23, 2025)."},{"key":"10.1016\/j.bmc.2026.118645_bb0200","unstructured":"Schr\u00f6dinger Release 2024\u20133: Desmond Molecular Dynamics System, D. E. Shaw Research, New York, NY, 2024. Maestro-Desmond Interoperability Tools, Schr\u00f6dinger, New York, NY, 2024. (n.d.)."},{"key":"10.1016\/j.bmc.2026.118645_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118416","article-title":"Phthalimide\u2013benzoic acid hybrids as potent aldose reductase inhibitors: synthesis, enzymatic kinetics, and in silico characterization","volume":"131","author":"Hoti","year":"2025","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2026.118645_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108788","article-title":"N-substituted phthalimide\u2013carboxylic acid hybrids as dual-targeted aldose reductase inhibitors: synthesis, mechanistic insights, and cancer-relevant profiling","volume":"163","author":"Zognjani","year":"2025","journal-title":"Bioorg Chem"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096808962600101X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096808962600101X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:44:59Z","timestamp":1780101899000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096808962600101X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":42,"alternative-id":["S096808962600101X"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118645","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Wee1-targeting inhibitors: From virtual screening to lead discovery","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118645","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"118645"}}